Investor directory

ARCH Venture Partners

ARCH Venture Partners, L.P. is a private equity and venture capital firm founded in 1986 and based in Chicago, Illinois, with additional offices across North America and South America. The firm specializes in early-stage and growth capital investments, primarily focusing on life sciences and biotechnology, but also covering a wide array of technology sectors such as advanced materials, communications technologies, and information technology. ARCH is recognized for its role in commercializing innovations developed at academic research institutions and national laboratories. It has raised over $3 billion through ten venture funds and has invested in more than 150 companies, often co-founding them with leading scientists and entrepreneurs. The firm typically invests between $50,000 and $150 million per company, aiming to enter at seed rounds to minimize risk, and seeks a seat on the Board of Directors for its portfolio companies. While primarily investing in the United States, ARCH also targets opportunities in Canada, Europe, and select countries in Asia, focusing on underserved geographic markets rich in scientific research and technological talent.

Focus

TherapeuticsSeries AScale StageEarly VentureSeries BShow more
http://www.archventure.com
https://crunchbase.com/organization/arch-venture-partners
https://linkedin.com/company/arch-venture-partners
https://signal.nfx.com/firms/arch-venture-partners
https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=18847
https://www.privateequityinternational.com/database/#/profile?id=6376
8755 W. Higgins Rd., Suite 1025 Chicago, IL 60631
999 Third Ave., Suite 3400 Seattle, WA 98104
1700 Owens St., Suite 535 San Francisco, CA 94158
5001 Plaza on the Lake Blvd., Suite 103 Austin, TX 78746

Paul Berns

Managing Director

Reetika Bhardwaj

Associate

Kristina M. Burow

Managing Director

Clinton Bybee

Co-Founder and Managing Director

Keith L. Crandell

Co-Founder and Managing Director

David Cruikshank

Partner

SU Fu

Senior Associate

George S. Golumbeski

Venture Partner

Edgar Hotard

Venture Partner

Sean Kendall

Principal

Jay Kocherlakota

Senior Associate

Jay Markowitz

Senior Partner

Mark McDonnell

Managing Director, CFO and CAO

Peter Mintun

Associate

Robert T. Nelsen

Co-Founder and Managing Director

Ari Nowacek

Principal

Corey Ritter

Principal

Carol Suh

Partner

Paul Thurk

Managing Director

Past deals in Life Science

Slingshot Biosciences

Series A in 2023
Slingshot Biosciences aims to bring simple, elegant, and cost-effective solutions to common problems facing research and development programs. Our technology platform will make a significant bottom-line impact on the speed and cost of early-stage discovery, research and development programs.

Be Biopharma

Series B in 2022
Be Biopharma, Inc. is focused on developing innovative therapeutics derived from engineered B-cells within the immune system. The company aims to address significant limitations associated with existing cell and gene therapies, such as the challenges of administering multiple doses, unpredictable patient reactions, and the necessity of potentially harmful chemotherapy regimens prior to treatment. Be Biopharma's approach allows for the creation of durable therapies that can be re-administered without toxic conditioning, making these treatments suitable for a range of diseases, including cancer, autoimmune disorders, and infectious diseases. Founded in 2020, Be Biopharma is headquartered in Cambridge, Massachusetts.

LifeMine Therapeutics

Series C in 2022
LifeMine Therapeutics, Inc., a biotechnology company, engages in the genomic discovery of new drug modalities from eukaryotic microbes. It utilizes an integrated genomically-enabled drug discovery platform to discover and develop a pipeline of new drugs from fungi. The company was incorporated in 2016 and is based in Cambridge, Massachusetts with an additional office in New York, New York.

Singleron Biotechnologies

Series B in 2021
Singleron Biotechnologies is a developer and provider of clinical diagnosis, health management and drug development products and services. The company is dedicated to applying single cell analysis techniques and has obtained a world wide exclusive IP license from Yale University for its uniquely designed microfluidic single cell processing device, and has developed the innovative SCOPE single-cell pre-sequencing preparation system based on this microfluidic device.

Slingshot Biosciences

Series A in 2021
Slingshot Biosciences aims to bring simple, elegant, and cost-effective solutions to common problems facing research and development programs. Our technology platform will make a significant bottom-line impact on the speed and cost of early-stage discovery, research and development programs.

Treeline Biosciences

Series A in 2021
Treeline Biosciences is a biotech company building transformative precision medicines for patients with cancer and other serious conditions. The company was founded in 2021 and is headquartered in Stamford, CT.

Locanabio

Series B in 2020
Locanabio, Inc., is an RNA-targeting gene therapy company focused on developing therapies for patients with severe neurodegenerative, neuromuscular, and retinal diseases.

SciNeuro

Series A in 2020
SciNeuro Pharmaceuticals develops medicines for patients with central nervous system (CNS) diseases. The company is based in Shanghai, China.

Resilience

Series B in 2020
Resilience, formally known as National Resilience, Inc., is a biopharmaceutical manufacturing and technology company established in 2020 and headquartered in La Jolla, California. The company specializes in end-to-end manufacturing and development solutions, focusing on advanced manufacturing technologies for various therapeutic modalities, including cell and gene therapies, viral vectors, vaccines, and proteins. Resilience is committed to expanding access to complex medicines and ensuring the stability of biopharmaceutical supply chains against potential disruptions. Through its innovative approaches, the company aims to enhance the efficiency and security of biopharmaceutical production, ultimately contributing to improved healthcare outcomes.

Singleron Biotechnologies

Series A in 2020
Singleron Biotechnologies is a developer and provider of clinical diagnosis, health management and drug development products and services. The company is dedicated to applying single cell analysis techniques and has obtained a world wide exclusive IP license from Yale University for its uniquely designed microfluidic single cell processing device, and has developed the innovative SCOPE single-cell pre-sequencing preparation system based on this microfluidic device.

Glympse Bio

Series B in 2020
Glympse Bio, Inc. is focused on developing modular nanoparticle sensors for diagnostics in fibrosis, cancer, immunology, and infectious diseases, as well as for monitoring drug response. The company utilizes engineered diagnostic agents that assess disease states within the body and convey this information to urine for analysis. Its flagship product, Glympse Inside, serves as a pan-disease engine intended to enhance disease monitoring and treatment response. Founded in 2015 and based in Cambridge, Massachusetts, Glympse Bio's innovative platform technology originated at MIT and is backed by a team of experts in nanomedicine and biomedical engineering.

Sana Biotechnology

Series A in 2020
Sana Biotechnology focuses on creating and delivering engineered cells as medicine for patients. Recent scientific advances make it possible to reprogram cells in the body or replace damaged cells and tissues, creating a new class of medicines to treat a broad array of diseases. The company is a team of scientists, clinicians and biotechnology veterans focused on creating an enduring company that makes meaningful medicines and will change the approach in treating diseases.

One BioMed

Series A in 2019
One BioMed Pte. Ltd. is a Singapore-based company that specializes in integrated molecular diagnostics services. Established in 2015, it focuses on delivering advanced medical diagnostic solutions to enhance patient care. The company's offerings aim to improve the accuracy and efficiency of disease detection and monitoring, contributing to better health outcomes. Through its innovative approaches, One BioMed is positioned to play a significant role in the evolving landscape of medical diagnostics.

Locanabio

Series A in 2019
Locanabio, Inc., is an RNA-targeting gene therapy company focused on developing therapies for patients with severe neurodegenerative, neuromuscular, and retinal diseases.

Vir

Series B in 2019
Vir Biotechnology, Inc. is a clinical-stage immunology company based in San Francisco, California, focused on developing therapeutic products to treat and prevent serious infectious diseases. The company employs a combination of innovative technologies and scientific expertise to enhance the immune response against pathogens. Its pipeline includes several product candidates, such as VIR-2218 and VIR-3434 for hepatitis B, VIR-2482 for influenza A, VIR-1111 for HIV, and VIR-2020 for tuberculosis. Vir's approach integrates various technology platforms, including antibodies, T cells, and small interfering RNA, to manipulate pathogen-host interactions. The company collaborates with multiple organizations, including the Bill & Melinda Gates Foundation, the National Institutes of Health, and several pharmaceutical companies, to advance its research and development efforts. Additionally, Vir has established agreements for the manufacturing of SARS-CoV-2 antibodies, positioning itself to address emerging infectious diseases. Founded in 2016, Vir Biotechnology aims to make significant advancements in the fight against viral diseases.

Sana Biotechnology

Seed Round in 2019
Sana Biotechnology focuses on creating and delivering engineered cells as medicine for patients. Recent scientific advances make it possible to reprogram cells in the body or replace damaged cells and tissues, creating a new class of medicines to treat a broad array of diseases. The company is a team of scientists, clinicians and biotechnology veterans focused on creating an enduring company that makes meaningful medicines and will change the approach in treating diseases.

Glympse Bio

Series A in 2018
Glympse Bio, Inc. is focused on developing modular nanoparticle sensors for diagnostics in fibrosis, cancer, immunology, and infectious diseases, as well as for monitoring drug response. The company utilizes engineered diagnostic agents that assess disease states within the body and convey this information to urine for analysis. Its flagship product, Glympse Inside, serves as a pan-disease engine intended to enhance disease monitoring and treatment response. Founded in 2015 and based in Cambridge, Massachusetts, Glympse Bio's innovative platform technology originated at MIT and is backed by a team of experts in nanomedicine and biomedical engineering.

AgBiome

Series C in 2018
AgBiome, LLC is a biotechnology company based in Durham, North Carolina, that focuses on developing innovative biological products for the agriculture industry. Founded in 2012, AgBiome utilizes advanced genomics and screening technologies to identify plant-associated microbes that enhance plant health, pest resistance, and crop yields. The company manufactures fungicides to protect crops from soil-borne and foliar diseases while also employing a platform that captures and screens diverse microbes for their effectiveness against insects, diseases, and nematodes. AgBiome collaborates with leading agricultural firms to accelerate its discovery process and deliver solutions that address critical challenges in global food production. With a workforce of approximately 87 employees and a state-of-the-art laboratory and greenhouse facility in the Research Triangle Park, AgBiome aims to provide sustainable and effective solutions for farmers facing significant agricultural issues.

Brii Biosciences

Venture Round in 2018
Brii Biosciences is a developer of bio-pharmaceutical medicines intended to provide medical solutions to Chinese patients to fulfill their health and treatment needs. The company's medicines focuses on infectious disease drug development and commercialization in China and leverage technology and data to drive improvements to the Chinese healthcare system and outcomes for patients, enabling patients to get access to better treatments and cures for life-threatening diseases.

Biopalette

Seed Round in 2018
Biopalette is a operator of a platform intended to offer gene-editing techniques. Bio Palette plans to develop our business in three fields, classified based on the type of cells targeted for genome editing.

LifeMine Therapeutics

Series A in 2017
LifeMine Therapeutics, Inc., a biotechnology company, engages in the genomic discovery of new drug modalities from eukaryotic microbes. It utilizes an integrated genomically-enabled drug discovery platform to discover and develop a pipeline of new drugs from fungi. The company was incorporated in 2016 and is based in Cambridge, Massachusetts with an additional office in New York, New York.

Biopalette

Venture Round in 2017
Biopalette is a operator of a platform intended to offer gene-editing techniques. Bio Palette plans to develop our business in three fields, classified based on the type of cells targeted for genome editing.

Vir

Venture Round in 2017
Vir Biotechnology, Inc. is a clinical-stage immunology company based in San Francisco, California, focused on developing therapeutic products to treat and prevent serious infectious diseases. The company employs a combination of innovative technologies and scientific expertise to enhance the immune response against pathogens. Its pipeline includes several product candidates, such as VIR-2218 and VIR-3434 for hepatitis B, VIR-2482 for influenza A, VIR-1111 for HIV, and VIR-2020 for tuberculosis. Vir's approach integrates various technology platforms, including antibodies, T cells, and small interfering RNA, to manipulate pathogen-host interactions. The company collaborates with multiple organizations, including the Bill & Melinda Gates Foundation, the National Institutes of Health, and several pharmaceutical companies, to advance its research and development efforts. Additionally, Vir has established agreements for the manufacturing of SARS-CoV-2 antibodies, positioning itself to address emerging infectious diseases. Founded in 2016, Vir Biotechnology aims to make significant advancements in the fight against viral diseases.

UNITY Biotechnology

Series B in 2016
Unity Biotechnology, Inc. is a biotechnology company dedicated to the research and development of therapeutics aimed at extending human health span. The company is focused on creating senolytic medicines that target and eliminate senescent cells, which are associated with various aging-related diseases. Its lead drug candidates include UBX0101, currently in Phase II clinical trials for musculoskeletal disorders and Phase Ib trials for knee osteoarthritis; UBX1325, in Phase I trials for diabetic macular edema; and UBX1967, targeting ophthalmologic diseases. Additionally, Unity is exploring therapeutic programs for pulmonary, neurological, kidney, and liver disorders. Founded in 2009 and headquartered in South San Francisco, California, Unity Biotechnology was formerly known as Forge, Inc. before rebranding in 2015.

Genomics Medicine Ireland

Series A in 2016
Genomics Medicine Ireland is a life sciences company focused on conducting extensive research studies throughout Ireland to explore the connections between the human genome, health, and disease. By analyzing genetic information, the company aims to deepen the understanding of how genetics influences various health outcomes and disease susceptibility. Through its research initiatives, Genomics Medicine Ireland seeks to contribute valuable insights that could inform future medical practices and enhance healthcare delivery.

AgBiome

Series B in 2015
AgBiome, LLC is a biotechnology company based in Durham, North Carolina, that focuses on developing innovative biological products for the agriculture industry. Founded in 2012, AgBiome utilizes advanced genomics and screening technologies to identify plant-associated microbes that enhance plant health, pest resistance, and crop yields. The company manufactures fungicides to protect crops from soil-borne and foliar diseases while also employing a platform that captures and screens diverse microbes for their effectiveness against insects, diseases, and nematodes. AgBiome collaborates with leading agricultural firms to accelerate its discovery process and deliver solutions that address critical challenges in global food production. With a workforce of approximately 87 employees and a state-of-the-art laboratory and greenhouse facility in the Research Triangle Park, AgBiome aims to provide sustainable and effective solutions for farmers facing significant agricultural issues.

UNITY Biotechnology

Series A in 2015
Unity Biotechnology, Inc. is a biotechnology company dedicated to the research and development of therapeutics aimed at extending human health span. The company is focused on creating senolytic medicines that target and eliminate senescent cells, which are associated with various aging-related diseases. Its lead drug candidates include UBX0101, currently in Phase II clinical trials for musculoskeletal disorders and Phase Ib trials for knee osteoarthritis; UBX1325, in Phase I trials for diabetic macular edema; and UBX1967, targeting ophthalmologic diseases. Additionally, Unity is exploring therapeutic programs for pulmonary, neurological, kidney, and liver disorders. Founded in 2009 and headquartered in South San Francisco, California, Unity Biotechnology was formerly known as Forge, Inc. before rebranding in 2015.

AgBiome

Venture Round in 2014
AgBiome, LLC is a biotechnology company based in Durham, North Carolina, that focuses on developing innovative biological products for the agriculture industry. Founded in 2012, AgBiome utilizes advanced genomics and screening technologies to identify plant-associated microbes that enhance plant health, pest resistance, and crop yields. The company manufactures fungicides to protect crops from soil-borne and foliar diseases while also employing a platform that captures and screens diverse microbes for their effectiveness against insects, diseases, and nematodes. AgBiome collaborates with leading agricultural firms to accelerate its discovery process and deliver solutions that address critical challenges in global food production. With a workforce of approximately 87 employees and a state-of-the-art laboratory and greenhouse facility in the Research Triangle Park, AgBiome aims to provide sustainable and effective solutions for farmers facing significant agricultural issues.

AgBiome

Series A in 2013
AgBiome, LLC is a biotechnology company based in Durham, North Carolina, that focuses on developing innovative biological products for the agriculture industry. Founded in 2012, AgBiome utilizes advanced genomics and screening technologies to identify plant-associated microbes that enhance plant health, pest resistance, and crop yields. The company manufactures fungicides to protect crops from soil-borne and foliar diseases while also employing a platform that captures and screens diverse microbes for their effectiveness against insects, diseases, and nematodes. AgBiome collaborates with leading agricultural firms to accelerate its discovery process and deliver solutions that address critical challenges in global food production. With a workforce of approximately 87 employees and a state-of-the-art laboratory and greenhouse facility in the Research Triangle Park, AgBiome aims to provide sustainable and effective solutions for farmers facing significant agricultural issues.

TRELYS

Seed Round in 2013
Trelys, Inc. operates in the biotechnology sector. The company was incorporated in 2012 and is based in San Francisco, California.

Permeon Biologics

Venture Round in 2011
Permeon Biologics is focused on improving human health through its innovative Intraphilin Technology Platform. This platform identifies naturally occurring human proteins known for their ability to enhance cellular uptake and permeate cell membranes effectively. By leveraging these "supercharged proteins," Permeon Biologics aims to develop a new generation of therapeutic drugs that can deliver functional proteins capable of replacing or restoring defective cellular pathways associated with various diseases. This approach represents a significant advancement in the field of intracellular biologics, positioning the company at the forefront of therapeutic innovation.

Qwell Pharmaceuticals

Series A in 2009
Qwell's goal is to develop a new family of small-molecule drugs, derived from a plant source, that have a potent ability to fight tumors and excess inflammation of skin cells.

Magen BioSciences

Series A in 2006
Magen BioSciences is a Biotechnology company located in 100 Beaver Street, Suite 101, Waltham, MA, United States.